CAJ | 학술논문

AIM:The role of intravenous pantoprazole in treatment ofpatients with high-risk bleeding peptic ulcers followingendoscopic hemostasis remains uncertain. We thereforeconducted the pilot prospective randomized study to assesswhether intravenous pantoprazole could improve theefficacy of H2-antagonist as an adjunct treatment followingendoscopic injection therapy for bleeding ulcers.METHODS: Patients with active bleeding ulcers or ulcerswith major signs of recent bleeding were treated with distilledwater injection. After hemostasis was achieved, they wererandomly assigned to receive intravenous pantoprazole orranitidine.RESULTS: One hundred and two patients were enrolled inthis prospective trial. Bleeding recurred in 2 patients (4%) inthe pantoprazole group (n = 52), as compared with 8 (16%)in the ranitidine group (n = 50). The rebleeding rate wassignificantly lower in the pantoprazole group (P = 0.04).There were no statistically significant differences betweenthe groups with regard to the need for emergency surgery(0% vs 2%), transfusion requirements (4.9±5.9 vs 5.7±6.8units), hospital days (5.9±3.2 vs 7.5±5.0 d) or mortality(2% vs 2%).CONCLUSION: Pantoprozole is superior to ranitidine asan adjunct treatment to endoscopic injection therapy inhigh-risk bleeding ulcers.